NanJing Pharmaceutical Co Ltd
SSE:600713
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (9.4), the stock would be worth ¥5.09 (11% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 10.5 | ¥5.7 |
0%
|
| 3-Year Average | 9.4 | ¥5.09 |
-11%
|
| 5-Year Average | 9.8 | ¥5.33 |
-6%
|
| Industry Average | 26.2 | ¥14.21 |
+149%
|
| Country Average | 28.8 | ¥15.63 |
+174%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
NanJing Pharmaceutical Co Ltd
SSE:600713
|
7.2B CNY | 10.5 | 11.5 | |
| US |
|
Mckesson Corp
NYSE:MCK
|
101.9B USD | 16.5 | 23.5 | |
| US |
|
Cencora Inc
NYSE:COR
|
59.9B USD | 13.1 | 36.9 | |
| US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
59.4B USD | 13 | 36.6 | |
| US |
|
Cardinal Health Inc
NYSE:CAH
|
47.2B USD | 13.8 | 28.4 | |
| AU |
|
Sigma Healthcare Ltd
ASX:SIG
|
32.1B AUD | 26.2 | 35.3 | |
| CN |
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
62.9B CNY | 8.6 | 11 | |
| US |
|
Henry Schein Inc
NASDAQ:HSIC
|
9B USD | 11.1 | 22.6 | |
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
59.8B CNY | 16.5 | 21.1 | |
| KR |
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW | 59.9 | 89.6 | |
| CN |
|
Sinopharm Group Co Ltd
HKEX:1099
|
61B HKD | 0.5 | 7.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 16.3 |
| Median | 28.8 |
| 70th Percentile | 53.1 |
| Max | 49 021 |
Other Multiples
NanJing Pharmaceutical Co Ltd
Glance View
Nanjing Pharmaceutical Co., Ltd. engages in the service of pharmaceutical distribution. The company is headquartered in Nanjing, Jiangsu and currently employs 5,062 full-time employees. The firm's principal businesses include the pharmaceutical wholesale, pharmaceutical retail, pharmaceutical-Internet + business, as well as the pharmaceutical third-party logistics services. The firm mainly conducts its business in domestic market.
